Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Pancreatic Cancer Clinical Trial

Official title:

A Prospective, Single Arm Study of Nimotuzumab Combined With Gemcitabine and Nab-paclitaxel as Conversion Therapy in Pancreatic Cancer With Liver Metastasis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06405685
• Other study ID #: IST-Nim-PC-5
• Status: Recruiting
• Phase: Phase 2
• Start date: April 27, 2023
• Est. completion date: October 30, 2025

Study information

• Verified date: May 2023
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Huikai Li, Dr
• Phone: 186 2222 8639
• Email: tjchlhk[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG in the treatment of pancreatic cancer with liver metastasis. Patients will receive Nimotuzumab plus AG as conversion therapy, and imaging assessments (according to RECIST V.1.1 criteria) will be performed every two cycles (every two months) of conversion therapy. The main endpoint is R0 resection rate. Additional end points included resection rates, overall survival (OS), objective response rate (ORR), safety, etc.

Description:

This clinical study is designed as a prospective, open-label, single arm study to evaluate the clinical efficacy and safety of Nimotuzumab combined with AG (gemcitabine and nab-paclitaxel) in the treatment of pancreatic cancer with liver metastasis. Patients will receive Nimotuzumab plus AG as conversion therapy, and imaging assessments (according to RECIST V.1.1 criteria) will be performed every two cycles (every two months) of conversion therapy. The resectability of the primary pancreatic lesion and liver metastases will be judged based on NCCN guidelines and will be determined by a multidisciplinary team of experts. The main endpoint is R0 resection rate. Additional end points included resection rates, overall survival (OS), objective response rate (ORR), safety, etc.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: October 30, 2025
• Est. primary completion date: October 30, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. Age 18-75 years old, gender unlimited;

• 2. Histologically or cytologically confirmed pancreatic cancer with liver metastasis;

• 3. Pancreatic cancer with liver metastasis, which is considered to be potentially resectable judged by a multidisciplinary team;

• 4. Receive nimotuzumab-based conversion therapy for voluntary;

• 5. No prior tumor systemic therapy;

• 6. Measurable disease according to RECIST criteria v1.1;

• 7. Adequate organ and bone marrow function, defined as follows: hemoglobin=9.0 g/dL; absolute neutrophil count (ANC)=1.5×10^9/L; platelets=100×10^9/L; serum total bilirubin (TBIL)=3×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 5 times the upper limit of normal (ULN); serum creatinine=1.5×ULN or estimated creatinine clearance > 60 mL/min;

• 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

• 9. Life expectancy is expected to be =3 months;

• 10. Fertile subjects are willing to take contraceptive measures during the study period.

• 11. Good compliance and signed informed consent voluntarily.

Exclusion Criteria:

• 1. Refuse chemotherapy or surgery;

• 2. Other part (e.g. peritoneum, lung, bone, brain) metastasis;

• 3. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);

• 4. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;

• 5. Undergone major surgery within 30 days;

• 6. Use of EGFR-mab or EGFR-TKI within 30 days;

• 7. Known allergy to prescription or any component of the prescription used in this study;

• 8. With HIV, HPV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);

• 9. Grade 2 or above toxicity from prior treatment that has not resolved (excluding anemia, alopecia, skin pigmentation, and chemotherapy-induced neurotoxicity)

• 10.Other reasons that are not suitable to participate in this study according to the researcher's judgment.

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• Nimotuzumab
Nimotuzumab 400 mg will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.
• AG
Patients will receive AG as conversion therapy up to 6 months. Gemcitabine 1000 mg/m^2 will be administered on Day 1, 8, 15 of a 28-day cycle. nab-Paclitaxel 125 mg/m^2 will be administered on Day 1, 8, 15 of a 28-day cycle by intravenous (IV) administration up to 6 cycles. Imaging (CT or MRI) and tumor markers (such as CA19-9) will be assessed every two cycles of the conversion therapy, until met the criteria of resection and underwent surgery.

Locations

Country	Name	City	State
China	Tianjin Medical University Cancer Institute and Hospital	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Tianjin Medical University Cancer Institute and Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	R0 resection rate	The Proportion of patients who achieved R0 resection (incisal edge>1cm)	Up to 6 months
Secondary	resection rate	The proportion of patients who underwent surgery.	Up to 18 months
Secondary	overall survival (OS)	The time from the beginning of treatment to death due to any cause.	Up to 18 months
Secondary	Objective response rate (ORR)	Objective response rate (ORR), including complete response (CR) and partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT/MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions.	Up to 18 months
Secondary	tumor-related markers	To explore the influence of tumor-related markers (such as CA199,EGFR) on prognosis.	Up to 18 months
Secondary	adverse events	Frequency and severity of adverse events.	Up to 30 days after last administration